Chamindi Seneviratne, MD

Riga Stradins University (Medical Academy of Latvia), Riga, Latvia

University of Texas Health Science Center at San Antonio, Texas

University of Virginia, Charlottesville, Va

Addiction genomics, pharmacogenetics, biomarkers, Alcoholism, Substance use disorders, addiction phase-1 trials

Seneviratne C and Johnson B.A. Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. Alcohol Res. 2015; 37(1): 15–28.

Li MD, Wang J, Niu T, Ma JZ, Seneviratne C, Ait-Daoud N, Saadvandi J, Morris R, Weiss D, Campbell J, Haning W, Mawhinney DJ, Weis D, McCann M, Stock C, Kahn R, Iturriaga E, Yu E, Elkashef A, Johnson BA. Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction. BMC Med Genomics. 2014 Dec 12;7(1):65.

Yang Z^*, Seneviratne C^*, Wang S, Ma JZ, Payne TJ, Wang J, Li MD. Serotonin transporter and receptor genes significantly impact nicotine dependence through genetic interactions in both European American and African American smokers. Drug Alcohol Depend. 2013 May 1; 129(3):217-25. (^*Authors contributed equally)

Johnson, B.A., Seneviratne, C., Wang, X.Q., Ait-Daoud, N., & Li, M.D. (2013). Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry, 170(9):1020-31.

Seneviratne C, Johnson BA (2012). Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics. Front Psychiatry. Mar 28; 3:23.